Second- and third-line treatments in non-small cell lung cancer

Current Treatment Options in Oncology

Volumn 7, Issue 1, 2006, Pages 37-49

  Kumar, Atul ^b   Wakelee, Heather ^a  

^a STANFORD CANCER INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; BEXAROTENE; BMS 275183; BORTEZOMIB; CETUXIMAB; CYANOCOBALAMIN; DEXAMETHASONE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; EPOTHILONE B; EPOTHILONE D; EPOTHILONE DERIVATIVE; ERLOTINIB; GEFITINIB; GEMCITABINE; IFOSFAMIDE; IRINOTECAN; IXABEPILONE; LOPERAMIDE; NAVELBINE; PACLITAXEL; PEMETREXED; PLACEBO; PLATINUM DERIVATIVE; SORAFENIB; TAXANE DERIVATIVE; TOPOTECAN; UNINDEXED DRUG; VANDETANIB; VATALANIB;

ABDOMINAL PAIN; ACNE; ADVANCED CANCER; ALOPECIA; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ASTHENIA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BREATHING DISORDER; CANCER SURVIVAL; CLINICAL TRIAL; COGNITIVE DEFECT; CONJUNCTIVITIS; CORNEA ULCER; COST EFFECTIVENESS ANALYSIS; DEHYDRATION; DIARRHEA; DRUG CONTRAINDICATION; DRUG DOSE REGIMEN; DRUG ERUPTION; DRUG FATALITY; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG METABOLISM; DRUG POTENTIATION; DYSPNEA; EPIPHORA; EYE TOXICITY; FATIGUE; FEBRILE NEUTROPENIA; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL TOXICITY; HAIR LOSS; HUMAN; HYPERTENSION; HYPERTRIGLYCERIDEMIA; HYPOXIA; INFECTION; KERATITIS; LABORATORY TEST; LIVER DYSFUNCTION; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MUCOSA INFLAMMATION; MULTIMODALITY CANCER THERAPY; NAUSEA; NAUSEA AND VOMITING; NEUTROPENIA; PERIPHERAL EDEMA; PREDICTION; PROGNOSIS; PROTEINURIA; QT PROLONGATION; QUALITY OF LIFE; REVIEW; SENSORY NEUROPATHY; SEPSIS; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; TRANSAMINITIS; VOMITING;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS; DRUG APPROVAL; HUMANS; LUNG NEOPLASMS; PROGNOSIS; QUALITY OF LIFE; SALVAGE THERAPY; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 31344480099     PISSN: 15272729     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11864-006-0030-9     Document Type: Review

References (59)

1. Jemal A, Tiwari RC, Murray T, et al.: Cancer statistics, 2004. CA Cancer J Clin 2004, 54:8-29.
2. Parkin DM, Bray F, Ferlay J, Pisani P: Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001, 94:153-156.
3. Ettinger DS, Cox JD, Ginsberg RJ, et al.: NCCN Non-Small-Cell Lung Cancer Practice Guidelines. The National Comprehensive Cancer Network. Oncology (Williston Park) 1996, 10:81-111.
4. Outcomes of cancer treatment for technology assessment and cancer treatment guidelines. American Society of Clinical Oncology. J Clin Oncol 1996, 14:671-679.
5. Kelly K, Crowley J, Bunn PA Jr, et al.: Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non--small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol 2001, 19:3210-3218.
6. Schiller JH, Harrington D, Belani CP, et al.: Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002, 346:92-98.
7. Fossella F, Pereira JR, von Pawel J, et al.: Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol 2003, 21:3016-3024.
8. Sandler A, Gray R, Brahmer JR, et al.: Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC #704865) in patients with advanced non-squamous cell lung cancer (NSCLC): an Eastern Cooperative Oncology Group (ECOG) Trial--E4599 [abstract #LBA4]. J Clin Oncol 2005, 23:2s.
9. Shepherd FA, Dancey J, Ramlau R, et al.: Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000, 18:2095-2103.
10. Fossella FV, DeVore R, Kerr RN, et al.: Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol 2000, 18:2354-2362.
11. Hanna N, Shepherd FA, Fossella FV, et al.: Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004, 22:1589-1597.
12. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al.: Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005, 353:123-132.
13. Dancey J, Shepherd FA, Gralla RJ, Kim YS: Quality of life assessment of second-line docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: results of a prospective, randomized phase III trial. Lung Cancer 2004, 43:183-194.
14. Camps C, Massuti B, Jimenez AM, et al.: Second-line docetaxel administrated every 3 weeks versus weekly in advanced non-small-cell lung cancer (NSCLC): a Spanish Lung Cancer Group (SLCG) phase III trial [abstract 2514]. Proc Am Soc Clin Oncol 2003, 22:625.
15. Gridelli C, Gallo C, Di Maio M, et al.: A randomised clinical trial of two docetaxel regimens (weekly vs 3 week) in the second-line treatment of non-small-cell lung cancer. The DISTAL 01 study. Br J Cancer 2004, 91:1996-2004.
16. Schuette W, Nagel S, Serke M, et al.: Second-line chemotherapy for advanced non-small cell lung cancer (NSCLC) with weekly versus three-weekly docetaxel: results of a randomized phase III study [abstract 7036]. J Clin Oncol 2004, 22:625s.
17. Synold T, Newman E, Lenz H-J, et al.: Prospective evaluation of docetaxel (D) pharmacokinetics (PK) and toxicity in patients with tumor-related hepatic dysfunction (HD) [abstract 643]. Proc Am Soc Clin Oncol 1999, 18:168a.
18. Engels FK, Ten Tije AJ, Baker SD, et al.: Effect of cytochrome P450 3A4 inhibition on the pharmacokinetics of docetaxel. Clin Pharmacol Ther 2004, 75:448-454.
19. Eisenhauer EA, Vermorken JB: The taxoids. Comparative clinical pharmacology and therapeutic potential. Drugs 1998, 55:5-30.
20. Calvert H: Folate status and the safety profile of antifolates. Semin Oncol 2002, 29:3-7.
21. Bunn P, Paoletti P, Niyikiza C, et al.: Vitamin B12 and folate reduce toxicity of Alimta (pemetrexed disodium, LY231514, MTA), a novel antifolate/antimetabolite [abstract 300]. Proc Am Soc Clin Oncol 2001, 20:76a.
22. Scagliotti CV, Shin DM, Kindler HL, et al.: Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma. J Clin Oncol 2003, 21:1556-1561.
23. Tsao MS, Sakurada A, Cutz JC, et al.: Erlotinib in lung cancer--molecular and clinical predictors of outcome. N Engl J Med 2005, 353:133-144.
24. Fukuoka M, Yano S, Giaccone C, et al.: Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 2003, 21:2237-2246.
25. Kris MG, Natale RB, Herbst RS, et al.: Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003, 290:2149-2158.
26. Janne PA, Gurubhagavatula S, Yeap BY, et al.: Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, "Iressa") on an expanded access study. Lung Cancer 2004, 44:221-230.
27. Miller VA, Kris MG, Shah N, et al.: Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. J Clin Oncol 2004, 22:1103-1109.
28. Hirsch FR, Gandara DR, McCoy J, et al.: Increased EGFR gene copy number detected by FISH is associated with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma (BAC) (S0126) [abstract 7030]. J Clin Oncol 2005, 23:628s.
29. Huisman C, Smit EF, Giaccone G, Postmus PE: Second-line chemotherapy in relapsing or refractory non-small-cell lung cancer: a review. J Clin Oncol 2000, 18:3722-3730.
30. Crino L, Mosconi AM, Scagliotti G, et al.: Gemcitabine as second-line treatment for advanced non-small-cell lung cancer: a phase II trial. J Clin Oncol 1999, 17:2081-2085.
31. Sanchez R, Esteban E, Palacio I, et al.: Activity of weekly irinotecan (CPT-11) in patients with advanced non-small cell lung cancer pretreated with platinum and taxanes. Invest New Drugs 2003, 21:459-463.
32. Georgoulias V, Kouroussis C, Agelidou A, et al.: Irinotecan plus gemcitabine vs irinotecan for the second-line treatment of patients with advanced non-small-cell lung cancer pretreated with docetaxel and cisplatin: a multicentre, randomised, phase II study. Br J Cancer 2004, 91:482-488.
33. Stewart DJ: Update on the role of topotecan in the treatment of non-small cell lung cancer. Oncologist 2004, 9(Suppl 6):43-52.
34. Ramlau R, Gervais R, Krzakowski M, et al.: Oral topotecan demonstrates clinical activity in relapsed non-small cell lung cancer. Results from an open-label, phase III study (387) comparing oral topotecan to intravenous docetaxel [abstract 7017]. J Clin Oncol 2005, 23:625s.
35. Chen YM, Perng RP, Lin WC, et al.: Phase II study of docetaxel and gemcitabine combination chemotherapy in non-small-cell lung cancer patients failing previous chemotherapy. Am J Clin Oncol 2002, 25:509-512.
36. Munoz A, Rubio I, Mane JM, et al.: Phase II study of docetaxel/vinorelbine in patients with non-small-cell-lung cancer previously treated with platinum-based chemotherapy. Clin Lung Cancer 2002, 4:168-173.
37. Popa IE, Stewart K, Smith FP, Rizvi NA: A phase II trial of gemcitabine and docetaxel in patients with chemotherapy-naive, advanced non-small cell lung carcinoma. Cancer 2002, 95:1714-1719.
38. Font A, Sanchez JM, Taron M, et al.: Weekly regimen of irinotecan/docetaxel in previously treated non-small cell lung cancer patients and correlation with uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) polymorphism. Invest New Drugs 2003, 21:435-443.
39. Niho S, Kubota K, Goto K, et al.: Combination second-line chemotherapy with gemcitabine and docetaxel for recurrent non-small-cell lung cancer after platinum-containing chemotherapy: a phase I/II trial. Cancer Chemother Pharmacol 2003, 52:19-24.
40. Frasci G, Comella P, Thomas R, et al.: Biweekly docetaxel-irinotecan with filgrastim support in pretreated breast and non-small-cell lung cancer patients. A phase I study. Cancer Chemother Pharmacol 2004, 53:25-32.
41. Grossi F, Belvedere O, Rossetto C, et al.: Irinotecan plus docetaxel in previously treated non-small cell lung cancer (NSCLC): an Alpe Adria Thoracic Oncology Multidisciplinary Group phase II study (ATOM 007) [abstract 7363]. J Clin Oncol 2004, 22:706s.
42. Keresztes RS, Socinski MA, Bonomi P, et al.: Phase II randomized trial of irinotecan/docetaxel (ID) or irinotecan/gemcitabine (IG) with or without celecoxib (CBX) in 2nd-line treatment of non-small-cell lung cancer (NSCLC) [abstract 7137]. J Clin Oncol 2004, 22:650s.
43. Matsui K, Hirashima T, Nitta T, et al.: A phase I/II study comparing regimen schedules of gemcitabine and docetaxel in Japanese patients with stage IIIB/IV non-small cell lung cancer. Jpn J Clin Oncol 2005, 35:181-187.
44. Pectasides D, Pectasides M, Farmakis D, et al.: Comparison of docetaxel and docetaxel-irinotecan combination as second-line chemotherapy in advanced non-small-cell lung cancer: a randomized phase II trial. Ann Oncol 2005, 16:294-299.
45. Kouroussis C, Mavroudis D, Kakolyris S, et al.: High incidence of pulmonary toxicity of weekly docetaxel and gemcitabine in patients with non-small cell lung cancer: results of a dose-finding study. Lung Cancer 2004, 44:363-368.
46. Gatzemeier U, Pluzanska A, Szczesna A, et al.: Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC) [abstract 7010]. J Clin Oncol 2004, 22:619s.
47. Herbst RS, Prager D, Hermann R, et al.: TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005, 23:5892-5899.
48. Davies AM, Lara PN, Lau DH, et al.: Intermittent erlotinib in combination with docetaxel (DOC): phase I schedules designed to achieve pharmacodynamic separation [abstract 7038]. J Clin Oncol 2005, 23:630s.
49. Bonomi P, Paz-Ares L, Langer C, et al.: Xyotax vs. docetaxel for the second-line treatment of non-small cell lung cancer (NSCLC): the Stellar 2 phase III study [abstract O-099]. Lung Cancer 2005, 49:S35.
50. Østerlind K, Sanchez JM, Zatloukal P, et al.: Phase I/II dose escalation trial of patupilone every 3 weeks in patients with non-small cell lung cancer [abstract 7110]. J Clin Oncol 2005, 23:647s.
51. Vansteenkiste JF, Breton JL, Sandler A, et al.: A randomized phase II study of epothilone analog BMS-247-550 in patients (pts) with non-small cell lung cancer (NSCLC) who have failed first-line platinum-based chemotherapy [abstract 2519]. Proc Am Soc Clin Oncol 2003, 22:626.
52. Yee L, Lynch TJ, Villalona-Calero M, et al.: A phase II study of KOS-862 (epothilone D) as second-line therapy in non-small cell lung cancer [abstract 7127]. J Clin Oncol 2005, 23:652s.
53. Herbst RS, Johnson DH, Mininberg E, et al.: Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J Clin Oncol 2005, 23:2544-2555.
54. Heymach JV, Johnson BE, Rowbottom JA, et al.: A randomized, placebo-controlled phase II trial of ZD6474 plus docetaxel in patient, with NSCLC [abstract 3023]. J Clin Oncol 2005, 23:197s.
55. Lilenbaum R, Bonomi P, Ansari R, et al.: A phase II trial of cetuximab as therapy for recurrent non-small cell lung cancer (NSCLC): final results [abstract 7036]. J Clin Oncol 2005, 23:629s.
56. Kim ES, Mauer AM, Tran HT, et al.: A phase II study of cetuximab, an epidermal growth factor receptor (EGFR) blocking antibody, in combination with docetaxel in chemotherapy refractory/resistant patients with advanced non-small cell lung cancer: final report [abstract 2581]. Proc Am Soc Clin Oncol 2003, 22:642.
57. Govindan R, Crowley J, Schwartzbberg L, et al.: Phase II trial of bexarotene capsules in patients with non-small-cell lung cancer (NSCLC) who have failed at least 2 prior systemic therapies for stage IIIB/IV disease [abstract 7116]. J Clin Oncol 2005, 23:648s.
58. Dragnev KH, Petty WJ, Shah S, et al.: A phase I trial of erlotinib and bexarotene as a targeted combination therapy for aerodigestive tract cancers [abstract 7093]. J Clin Oncol 2005, 23:643s.
59. Fanucchi MP, Fossella F, Fidias P, et al.: Bortezomib +/-docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC): a phase II study [abstract 7034]. J Clin Oncol 2005, 23:629s.